Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
420 questions in 57 reviews · Gut
current versionsNo studies 420 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
H2 receptor antagonists vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Proton pump inhibitors vs placebo or no prophylaxis Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Proton pump inhibitors vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs placebo or no prophylaxis Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs placebo or no prophylaxis Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Sucralfate vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs proton pump inhibitors Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs antacids Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs antacids Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs sucralfate Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs sucralfate Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Interventions vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Limitations Non‐invasive diagnostic tests for Helicobacter pylori infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Index test Non‐invasive diagnostic tests for Helicobacter pylori infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Duodenal stenting vs surgical palliation Health‐related quality of life · people with malignant gastric outlet obstruction Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil CRP (mg/dL) at end of study · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil Quality of life · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil Adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil Withdrawal due to adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil Proportion of patients achieving clinical remission · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil Proportion of patients achieving clinical response · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil CRP (mg/dL) at end of study · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil Adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil Serious adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil Withdrawal due to adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes (115 mg THC) vs placebo cigarettes Quality of life Short‐Form 36 health survey (SF‐36) · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes (115 mg THC) vs placebo cigarettes Serious adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes (115 mg THC) vs placebo cigarettes Withdrawal due to adverse events · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil Proportion of patients achieving clinical response · participants with active Crohn's disease Cannabis for the treatment of Crohn's disease (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes vs placebo Quality of life Inflammatory Bowel Disease Questionnaire (IBDQ) · participants with active ulcerative colitis Cannabis for the treatment of ulcerative colitis (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes vs placebo Adverse events · participants with active ulcerative colitis Cannabis for the treatment of ulcerative colitis (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes vs placebo Serious adverse events · participants with active ulcerative colitis Cannabis for the treatment of ulcerative colitis (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes vs placebo Withdrawal due to adverse events · participants with active ulcerative colitis Cannabis for the treatment of ulcerative colitis (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes vs placebo Clinical remission · participants with active ulcerative colitis Cannabis for the treatment of ulcerative colitis (2018) · Cochrane | no estimate extracted | NR | No studies |
Cannabis cigarettes vs placebo Clinical response · participants with active ulcerative colitis Cannabis for the treatment of ulcerative colitis (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention alone Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Long‐term mortality · people with acute pancreatitis Pharmacological interventions for acute pancreatitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · people with acute pancreatitis Pharmacological interventions for acute pancreatitis (2017) · Cochrane | no estimate extracted | NR | No studies |
On‐demand deprescribing vs continued use Cost/resource use · people with moderate GERD and mild esophagitis, mean age 48 to 57 years Deprescribing versus continuation of chronic proton pump inhibitor use in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy Cost analysis · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer) Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative… (2017) · Cochrane | no estimate extracted | NR | No studies |
Active cancer therapy combined with TCM vs active cancer therapy All‐cause mortality ‐ not reported · patients with oesophageal cancer Chinese herbal medicine for oesophageal cancer (2016) · Cochrane | no estimate extracted | NR | No studies |
Active cancer therapy combined with TCM vs active cancer therapy Median survival times ‐ not reported · patients with oesophageal cancer Chinese herbal medicine for oesophageal cancer (2016) · Cochrane | no estimate extracted | NR | No studies |
Active cancer therapy combined with TCM vs active cancer therapy Time to progression ‐ not reported · patients with oesophageal cancer Chinese herbal medicine for oesophageal cancer (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Short‐term mortality · people with necrotising pancreatitis Interventions for necrotising pancreatitis (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Organ failure · people with necrotising pancreatitis Interventions for necrotising pancreatitis (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events (number) · people with necrotising pancreatitis Interventions for necrotising pancreatitis (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Short‐term mortality · patients with pancreatic pseudocysts Management strategies for pancreatic pseudocysts (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital stay · patients with pancreatic pseudocysts Management strategies for pancreatic pseudocysts (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · patients with pancreatic pseudocysts Management strategies for pancreatic pseudocysts (2016) · Cochrane | no estimate extracted | NR | No studies |